ArticleCancer cell2013
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.
Article in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis.Oncotarget · 2016Pooled it
- Choline-dependent methionine metabolism supports leukemia progression.Communications biology · 2026Article
- Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.Blood · 2026Article
- A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression.Nature communications · 2025Article
- Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients.World journal of clinical oncology · 2025Article
- Mutant CEBPA promotes tolerance to inflammatory stress through deficient AP-1 activation.Nature communications · 2025Article
- Biological function and mechanism of NAT10 in cancer.Cancer innovation · 2025Review
- Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.Nature communications · 2024Article
- SOXC are critical regulators of adult bone mass.Nature communications · 2024Article
- Article
- Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.Scientific reports · 2023Article
- Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.American journal of clinical pathology · 2023Article
- Distinct and opposite effects of leukemogenicProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.Blood reviews · 2023Review
- Single-cell analyses reveal early thymic progenitors and pre-B cells in zebrafish.The Journal of experimental medicine · 2022Article
- NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression.Clinical and translational medicine · 2022Article
- Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair.Oncogene · 2022Article
- Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia.Blood cancer discovery · 2022Article
- Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedDiruscio, Annalisa [corrected to Di Ruscio, Annalisa]
Authors and funding
22 authors at 10 institutions in 8 countries.
Funding
Abstract
Mutation or epigenetic silencing of the transcription factor C/EBPα is observed in ∼10% of patients with acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target of C/EBPα whereby its expression is inversely correlated with C/EBPα activity. Downregulation of Sox4 abrogated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of leukemia-initiating cells (LICs) from both Sox4 overexpression and murine C/EBPα mutant AML models clustered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression resulting from C/EBPα inactivation contributes to the development of leukemia with a distinct LIC phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.